Neuropace, Inc.

Historical 13F Holders

Symbol
NPCE
CUSIP
641288105
All holders as of
Q2 2026
Type
Equity
Class
COM
Reported Value, Excluding Options
Total Filings

13D/G Filers

Investors who own more than 5% of a class must file a Schedule 13D or 13G. Each filer's latest filing for 641288105 since 12/18/2024, largest first.

Filer % of Class Filed
First Light Asset Management, LLC 13G/A
12.3% 9/4/2026
Event 8/31/2026
Polar Capital Holdings Plc 13G
9.1% 5/15/2025
Event 3/31/2025
Soleus Private Equity Fund I, L.P. 13G/A
8.9% 11/7/2025
Event 9/30/2025
Morgan Stanley 13G/A
8.3% 2/4/2025
Event 12/31/2024
Soleus Capital Master Fund, L.P. 13G/A
7.0% 8/5/2025
Event 6/30/2025
Under 5%, checked the "5 percent or less" box, or amended by a later filing (3)
Kent Lake PR LLC 13G/A
4.9% 2/14/2025
Event 12/31/2024
OrbiMed Advisors LLC 13G/A
4.4% 8/14/2026
Event 6/30/2026
KCK Ltd. 13G/A 0% 9/3/2025
Event 2/20/2025

13F Holders by Quarter

Period Filings Shares, Excl. Options Value, Excl. Options
2026 Q3 2 15.0 $206.00
2026 Q2 114 26.6 M $423 M
2026 Q1 115 26.5 M $348 M
2025 Q4 102 26.3 M $406 M
2025 Q3 84 26.0 M $268 M
2025 Q2 109 22.5 M $251 M
2025 Q1 94 23.9 M $294 M
2024 Q4 67 20.9 M $234 M
2024 Q3 52 14.8 M $103 M
2024 Q2 58 17.5 M $132 M
2024 Q1 62 18.4 M $242 M
2023 Q4 45 16.3 M $168 M
2023 Q3 26 18.1 M $176 M
2023 Q2 23 17.5 M $78.6 M
2023 Q1 25 17.7 M $82.0 M
2022 Q4 26 17.4 M $25.9 M
2022 Q3 29 18.2 M $68.1 M
2022 Q2 33 18.4 M $91.2 M
2022 Q1 41 18.2 M $150 M
2021 Q4 43 18.0 M $182 M
2021 Q3 41 11.2 M $177 M
2021 Q2 46 10.9 M $259 M